Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
First-line benmelstobart plus anlotinib versus sunitinib in advanced kidney cancer
A new immunotherapy called benmelstobart, which blocks the action of [...]
Combination treatment shows benefits in rare, aggressive kidney cancer
Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare [...]
Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Pembrolizumab plus axitinib shows sustained benefit in advanced kidney cancer
The final long-term follow-up data from the phase 3 KEYNOTE-426 [...]
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line treatment for metastatic kidney cancer
Treatment of advanced (metastatic) kidney cancer has improved considerably over [...]
Immunotherapy for the treatment of non-clear cell kidney cancer
There are several types of kidney cancer, the most common [...]
Combinations of pembrolizumab and targeted therapies for advanced clear cell kidney cancer
The KEYMAKER-U03 study is looking at different combinations of immunotherapy [...]
Kidney cancer research highlights from ASCO GU 2025
Every year, researchers from around the world gather at a [...]
Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer
Updated results from the phase 2 LITESPARK-003 trial with belzutifan [...]
